

Opinion

The management of exacerbations of chronic obstructive pulmonary disease in primary care

Definition of an acute exacerbation of Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) is a slowly progressive condition characterised by episodes of acute exacerbations, which have dramatic effects on the patient. An exacerbation of COPD is defined as "a worsening of the patient's condition, from the stable state and beyond normal day-to-day variation that is acute in onset and necessitates a change in regular medication".¹ Typically, patients will present with acute increasing dyspnoea combined with a productive cough and a change in the amount, viscosity, and colour of their sputum.²

Exacerbations range in severity from mild (causing few problems) to severe (associated with respiratory failure and hospital admission). There is evidence to suggest that up to 50% of patients suffering from an acute exacerbation will not report to a health care professional.³ Even mild exacerbations may be important and are associated with impaired health status and decline in lung function. While there is no formal classification of severity, one can classify admissions in terms of health care utilisation, ranging from mild (self-managed) to those involving unscheduled care:

- Visit to GP
- Out of hours visit
- A&E attendance
- Hospital admission

Cost of care

The cost of managing COPD within our society is huge, with direct costs to the National Health Service (NHS) estimated at £492 million, and indirect costs estimated at £981 million. Most of the costs are due to acute exacerbations. The average cost of a patient with COPD in the UK is £819.41. Of this, 60% is attributable to the management of acute exacerbations of COPD, and most of this cost is spent on secondary care treatment. Only 14% of the total cost of an "average COPD" patient is spent on treatment and investigation costs.⁴ Thus, reducing the frequency and severity of an acute exacerbation

of COPD by adopting a proactive approach centred on the patient will have benefits not only to the patient but also makes good financial sense.

Management of acute exacerbations within primary care

The proactive approach to managing acute exacerbations with patients encompasses four aspects:

1. Reducing exacerbation frequency
2. Providing self-management advice for patients suffering an exacerbation of COPD
3. Assessing and appropriately managing an exacerbation
4. Ensuring correct follow up of patients following an exacerbation

Reducing exacerbation frequency

The forthcoming National Institute for Health and Clinical Excellence (NICE) guidelines have examined the current evidence base for the use of Inhaled corticosteroids, inhaled combination inhalers (Inhaled corticosteroid and long-acting beta agonist) and inhaled long-acting muscarinic antagonists (LAMA) in reducing exacerbations rates in patients with COPD.⁵ Previously it was recommended that patients with a FEV₁ <50% predicted and 2 or more exacerbations should be treated with a combination inhaler. A recent study has shown that the use of a LAMA (Tiotropium) significantly reduced exacerbations compared to usual COPD care. The control group of usual care included patients on ICS and LABAs but excluded those on an anticholinergic inhaler.⁶ In addition the Inspire study showed comparable rates of acute exacerbations in patients taking either a combination inhaler or a LAMA.⁷ From this evidence it is proposed that combination inhalers (ICS+LABA) or a LAMA should be used in patients with an FEV₁<50% who remain breathless or suffer from exacerbations despite being on either a short acting bronchodilator or a LABA. Indeed in patients with a FEV₁<50% predicted who are already on one of these inhalers and con-

tinue to have breathlessness or recurring exacerbations, it is recommended that both inhalers should be used.

Pneumococcal vaccination and annual influenza vaccination are recommended for patients with COPD by both the Chief Medical Officer and by NICE guidelines. Although the evidence base is stronger for the impact of influenza vaccination on reducing COPD exacerbations than that for pneumococcal vaccination, both are highly recommended with all patients with COPD.

Providing self-management advice

The evidence base for the use of self-management plans (SMPs) is conflicting and sparse. However, there is evidence from a Cochrane review in 2004 that the prompt administration of oral steroids within three days of onset will reduce breathlessness and improve recovery time.⁹ There is also evidence on the prompt use of broad-spectrum antibiotic in reducing the recovery time from an acute exacerbation and reducing subsequent mortality.¹⁰ This evidence would suggest that the most simple SMP would entail advice on when to take these drugs at the onset of an acute exacerbation.¹¹ Therefore, in patients with moderate to severe COPD who have a history of recurrent exacerbations, the provision of a home supply of a broad-spectrum antibiotic and oral steroid would empower patients to start these therapies at an earlier phase of an acute exacerbation.

An instruction of when to alert the clinician following self-administration needs to be an integral part of the plan. Thus the steps involved in a patient SMP should include:

- Instruction on increasing bronchodilator use to the maximum
- Commencement of oral steroids if symptoms persist (30mg of prednisolone for 7-10 days)
- Starting a course of a broad spectrum antibiotic if the sputum becomes purulent
- How to recognise features of an exacerbation which indicate the need for urgent action e.g. when to call an ambulance

Table 1. Factors favouring management at home.
Adapted from NICE Guidelines⁵

• Able to cope at home	Yes
• Breathlessness	Mild
• General Condition	Good
• Level of activity	Good
• Cyanosis	No
• Worsening peripheral oedema	No
• Level of consciousness	Normal
• Already receiving long-term oxygen therapy (LTOT)	No
• Social circumstances	Good
• Acute confusion	No
• Rapid rate of onset	No
• Significant co-morbidity (particularly cardiac disease and/or Type 1 diabetes)	No
• SaO ₂ <90%	No
• Chances on Chest X-ray	No

• Follow-up arrangements

An example of a SMP can be viewed in our COPD Self Management opinion Sheet – see http://www.pcrs-uk.org/resources/os11_copd_self_man.pdf

Assessing and appropriately managing an exacerbation

The first response to an acute exacerbation should be from the patient in line with their SMP. However, many patients may present with previously-undiagnosed COPD. Patients presenting with features of an acute exacerbation of COPD should be seen as soon as reasonably possible since deterioration of their clinical state can be rapid. Thus, patients who are known to have a history of exacerbations should be flagged within practices so that they are identified early and can be fast tracked to consult their usual clinician. It is important to take a full clinical diagnosis to confirm both the previous diagnosis of COPD and the presence of an acute exacerbation. Whether a patient can be managed at home requires a full assessment. Factors that would suggest that admission to hospital for further assessment and management is necessary include:

Clinical history

- Unconfirmed or ambiguous diagnosis
- Poor social support
- Confusion and drowsiness
- Unremitting dyspnoea
- Chest pain

Clinical examination

- Pyrexia (and/or a history of rigors)
- Cyanosis
- New onset of peripheral oedema
- Co-morbid conditions - such as active heart failure or uncontrolled diabetes

Investigations

- Worsening hypoxia
- Pulse oximetry $\leq 90\%$

The decision to treat at home should also be dependent on the clinician's experi-

ence and confidence in managing acute exacerbations, their ability to provide accessible regular assessments during the exacerbation period, the services available to support the patient within their own homes, and the safety of the patient throughout the exacerbation period. There are a number of assessment tools available for clinicians in assessing the appropriateness of home management as opposed to hospital admission (see Table 1).

If managing the patient at home, it is incumbent on the clinician to assess the patient regularly at an appropriate frequency (which in many patients may be daily until the patient's condition is stable), to ensure that the patient is being treated with appropriate therapies as per their SMP, and to ensure appropriate review and subsequent referral following the exacerbation. NICE also recommends the use of the anti-viral drug, oseltamivir, during flu epidemics - although administration should be within 48 hours of the onset of symptoms. Zanamivir is not recommended in these circumstances as it may induce bronchospasm.

Practice protocols detailing the treatment and management of acute exacerbations can help to facilitate best practice and ensure consistency of care. The PCRS-UK have produced a protocol for the management of acute exacerbations which can be adapted by general practices.¹²

Ensuring correct follow-up of a patient following an acute exacerbation

It can take at least six weeks for a patient to recover fully from an acute exacerbation of COPD.¹³ Following an exacerbation a full review should be performed. Essential aspects of this review should include:

1. Ensuring the patient is on optimal medical therapy in line with NICE guidelines
2. Education to discuss self management and if appropriate smoking cessation
3. Referral to pulmonary rehabilitation - if

not undertaken before and if they fulfil criteria i.e. on optimised treatment and functionally disabled (MRC score ≤ 3)

4. Assessment of O₂ needs - either for long term O₂ therapy or ambulatory O₂

References

1. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbation. *Chest* 2000;**117**(5 Suppl 2):398-401 S.
2. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987;**106**(2):196-204.
3. Seemungal TA, Donaldson GC, Paul EA et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998;**157**(5 Pt 1):1418-22.
4. National clinical guideline on the management of chronic obstructive pulmonary disease in adults in primary and secondary care. National Collaborating Centre for Chronic Conditions. *Thorax* 2004;**59**(Suppl1):1-232.
5. National Institute for Health and Clinical Excellence (NICE) 2010. Chronic Obstructive Pulmonary Disease: national clinical guidelines for management of chronic obstructive pulmonary disease in adults in primary and secondary care. <http://www.nice.org.uk/guidance/index.jsp?action=download&o=46091>
6. Decramer M, Celli B, Kesten S et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. *Lancet* 2009;**374**(9696):1171-8.
7. Wedzicha JA, Calverley P, Seemungal TA et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. *Am J Respir Crit Care Med* 2008;**177**(1):19-26.
8. Poole PJ, Black PN. Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents. *Am J Respir Med* 2003;**2**(5):367-70.
9. Wood-Baker RR, Gibson PG, Hannay M, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005;Art. No.: CD001288. doi: 10.1002/14651858.CD001288.pub2.(1).
10. Ram FSF, Rodriguez-Roisin R, Granados-Navarrete A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006;Art. No.: CD004403. doi:10.1002/14651858.CD004403.pub2.(2).
11. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. *Lancet* 1999;**354**(9177):456-60.
12. Reilly S. Management of Acute Exacerbations of COPD. Protocol No. 2. Available from http://www.gpiag.org/nurses/protocol02_exacerbations_final.pdf
13. D E O'Donnell and C M Parker. COPD exacerbations • 3: Pathophysiology. *Thorax* 2006;**61**:354-61.

Date of Preparation: December 2007, **Revised:** June 2010 **Author:** Dr Noel O'Kelly, Leicestershire County and Rutland Community Health Services; GP Spilsby, Lincolnshire

Conflict of interest: Dr O'Kelly has provided consultancy and/or lectures for, and/or received travel bursaries for scientific meetings from, several pharmaceutical companies including AstraZeneca UK Ltd, GlaxoSmithKline, Boehringer-Ingelheim/Pfizer Ltd and Chiesi.

Editor: Dr Paul Stephenson, PCRS-UK **Editor-in-Chief:** Dr Mark Levy, PCRS-UK

Address for Correspondence: PCRS-UK, Smithy House, Waterbeck, Lockerbie, DG11 3EY, UK **Telephone:** +44 (0)121 351 4455 **Facsimile:** +44 (0)121 336 1914

Websites: <http://www.pcrs-uk.org>, <http://www.thepcrj.org> **Email:** info@pcrs-uk.org